Study S003213

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07284901
Acronym: KaiNETIC-2
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 1270
Start: 2026-01-12
Primary completion: 2028-03-27
Lead sponsor: Kailera
Conditions: Obesity With Diabetes; Overweight With Diabetes
Interventions: DRUG:Ribupatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO
Secondary identifiers: CTIS:2025-523510-87-00; NIH:2025

Registered primary outcomes

Doses 3 and 4 of Ribupatide Versus Placebo: Percent Change From Baseline in Body Weight at Week 76 [Baseline, Week 76]
Doses 3 and 4 of Ribupatide Versus Placebo: Change From Baseline in HbA1c at Week 76 [Baseline, Week 76]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0036322	UK patients being recruited for ribupatide trials , Pharmaceutical journal/The pharmaceutical journal	2026	Other trial	DOI	cites ClinicalTrials.gov:NCT07284901